City of Hope

City of Hope, a NCI-designated Comprehensive Cancer Center

Page Title

Skip Navigation

Global Navigation



Border Border
  
Click here to login to Secure Web Site   (authorized users only)  
  
Search results:  54  Clinical trial(s) found  (Page 1 of 3 )
Results per page: 25 50 100 All 1-25 Trials Jump to page:

The following studies are available for :
COH Protocol Number: 14265 ClinicalTrials.gov Number: NCT01625234

Principal Investigator: Karen Reckamp, MD
Sponsor: Industrial

Title:  Phase 1/2, First-in-Human, Dose-Escalation Study of X-396 in Patients With Advanced Solid Tumors and Expansion Phase in Patients With ALK-positive Non-Small Cell Lung Cancer

COH Protocol Number: 14231 ClinicalTrials.gov Number: NCT02220842

Principal Investigator: Leslie Popplewell, MD
Sponsor: Industrial

Title:  A Phase 1b Sudy of the Safety and Pharmacology of MPDL3280A Administered with Obinutuzamab in Patients with Relpased/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma

COH Protocol Number: 14212 ClinicalTrials.gov Number: NCT01998971

Principal Investigator: Amrita Krishnan, MD
Sponsor: Industrial

Title:  An Open-Label, Multicenter, Phase 1b Study of JNJ-54767414 (HuMaxCD38) (Anti-CD38 Monoclonal Antibody) in Combination with Backbone Regimens for the Treatment of Subjects with Multiple Myeloma

COH Protocol Number: 14179 ClinicalTrials.gov Number: NCT01526928

Principal Investigator: Karen Reckamp, MD
Sponsor: Industrial

Title:  A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

COH Protocol Number: 14171 ClinicalTrials.gov Number: NCT02216890

Principal Investigator: Sumanta Pal, MD
Sponsor: Industrial

Title:  A Phase 1 Trial of SGN-CD70A in Patients with CD70-positive Malignancies

COH Protocol Number: 14167 ClinicalTrials.gov Number: NCT02206763

Principal Investigator: Karen Reckamp, MD
Sponsor: Industrial

Title:  A Phase 1b Study of Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naïve Metastatic Non-Small Cell Lung Cancer (NSCLC)

COH Protocol Number: 14166 ClinicalTrials.gov Number: NCT01786135

Principal Investigator: Robert Chen, MD
Sponsor: Industrial

Title:  A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients with Relapsed or Refractory B-lineage Non-Hodgkins Lymphoma

COH Protocol Number: 14161 ClinicalTrials.gov Number: NCT02250157

Principal Investigator: Marwan Fakih, MD
Sponsor: Industrial

Title:  A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects with Advanced Malignancies

COH Protocol Number: 14160 ClinicalTrials.gov Number: NCT01962792

Principal Investigator: Chatchada Karanes, MD
Sponsor: Industrial

Title:  A Multicenter Phase 1/2b Study of the Bruton’s Tyrosine Kinase Inhibitor, Ibrutinib (PCI-32765), in Combination with Carfilzomib (Kyprolis™) in Subjects with Relapsed or Relapsed and Refractory Multiple Myeloma

COH Protocol Number: 14158 ClinicalTrials.gov Number: NCT02319369

Principal Investigator: Joseph Rosenthal, MD
Sponsor: Industrial

Title:  A Phase 1 Dose Escalation Study of DS-3032B, an Oral MDM2 Inhibitor, in Subjects with Acute Myelogenous Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myleogenous Leukemia (CML) in Blast Phase, or High-Risk Myelodysplastic Syndrome (MDS)

COH Protocol Number: 14157 ClinicalTrials.gov Number: NCT02354417

Principal Investigator: Anna Pawlowska, MD
Sponsor: Industrial

Title:  A Phase I Trial of a Single ProHema CB Product (EX Vivo Modulated Human Cord Blood Cells) Following Myeloablative Conditioning for Pediatric Patients with Hematologic Malignancies

COH Protocol Number: 14156 ClinicalTrials.gov Number: NCT02223598

Principal Investigator: Amrita Krishnan, MD
Sponsor: Industrial

Title:  A Phase 1, Dose-Escalation /Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Patients with Relapsed/Refractory Multiple Myeloma

COH Protocol Number: 14155 ClinicalTrials.gov Number: NCT02151903

Principal Investigator: Ryotaro Nakamura, MD
Sponsor: Industrial

Title:  An Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine administered in Patients with B-cell Non-Hodgkin Lymphoma (NHL)

COH Protocol Number: 14138 ClinicalTrials.gov Number: NCT02006485

Principal Investigator: Tanya Siddiqi, MD
Sponsor: Industrial

Title:  A Multi-Center Phase I/Ib Study Evaluating the Efficacy and Safety of Ublituximab, a Third- Generation Anti-CD20 Monoclonal Antibody, in Combination with TGR-1202, a Novel PI3k Delta Inhibitor; and Ibrutinib in Patients with B-cell Malignancies

COH Protocol Number: 14115 ClinicalTrials.gov Number: NCT02195869

Principal Investigator: Ryotaro Nakamura, MD
Sponsor: Industrial

Title:  A Multicenter, Open-Label, Phase 1b/2 Study of Ibrutinib In Steroid Dependent or Refractory Chronic Graft Versus Host Disease

COH Protocol Number: 14086 ClinicalTrials.gov Number: NCT02164006

Principal Investigator: Robert Chen, MD
Sponsor: Industrial

Title:  A Multi-center Phase I/Ib Study Evaluating the Efficacy and Safety of Brentuximab Vedotin in Combination with TGR-1202, a Novel PI3K Delta Inhibitor, in Patients with Hodgkins Lymphoma (HL)

COH Protocol Number: 14044 ClinicalTrials.gov Number: NCT02014558

Principal Investigator: Margaret O'Donnell, MD
Sponsor: Industrial

Title:  A Phase 1/2 Open-Label, Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP2215 in Patients with Relapsed or Refractory Acute Myeloid Leukemia

COH Protocol Number: 14036 ClinicalTrials.gov Number: NCT02120469

Principal Investigator: Yuan Yuan, MD, PhD
Sponsor: Institutional

Title:  Phase I/IB Trial of Eribulin and Everolimus in Patients with Triple Negative Metastatic Breast Cancer

COH Protocol Number: 14011 ClinicalTrials.gov Number: NCT02142049

Principal Investigator: Leslie Popplewell, MD
Sponsor: Industrial

Title:  A Multicenter Study of Ibrutinib and Lenalidomide in Combination with DA-EPOCH-R in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma

COH Protocol Number: 13474 ClinicalTrials.gov Number: NCT02113982

Principal Investigator: Anthony Stein, MD
Sponsor: Industrial

Title:  SL-401 in Patients with Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm

COH Protocol Number: 13472 ClinicalTrials.gov Number: NCT01769768

Principal Investigator: Vincent Chung, MD
Sponsor: Industrial

Title:  A Phase Ib, Multi-center, Two Parallel Group, Open-label, Drug-drug Interaction Study to Assess the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients with Advanced Solid Tumors

COH Protocol Number: 13431 ClinicalTrials.gov Number: NCT01868022

Principal Investigator: Karen Reckamp, MD
Sponsor: Industrial

Title:  Multi-arm, Non-randomized, Open-Label Phase IB Study to Evaluate GSK3052230 in Combination with Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects with Solid Malignancies and Deregulated FGF Pathway Signaling

COH Protocol Number: 13401 ClinicalTrials.gov Number: NCT02015819

Principal Investigator: Jana Portnow, MD
Sponsor: Institutional

Title:  A Phase I Study of Cytosine Deaminase-Expressing Neural Stem Cells in Combination with Oral 5-Fluorocytosine and Leucovorin for the Treatment of Recurrent High-Grade Gliomas

COH Protocol Number: 13395 ClinicalTrials.gov Number: NCT01925131

Principal Investigator: Margaret O'Donnell, MD
Sponsor: Cooperative Group

Title:  SWOG S1312: A Phase I Study of Inotuzumab Ozogamicin (NSC-772518) in Combination with CVP (Cyclophosphamide, Vincristine, Prednisone) for Patients with Relapsed/Refractory CD22-Positive Acute Leukemia (Including B-ALL, Mixed Phenotypic Leukemia, and Burkitt’s Leukemia)

COH Protocol Number: 13373 ClinicalTrials.gov Number: NCT02275039

Principal Investigator: Mihaela Cristea, MD
Sponsor: Institutional

Title:  A Phase I Study of a p53MVA Vaccine in Combination with Gemcitabine in Ovarian Cancer

 
Results per page: 25 50 100 All 1-25 Trials Jump to page:

 
 
  
NCI CCC LogoCity of Hope, An NCI-designated Comprehensive Cancer Center, is an innovative biomedical research, treatment and educational institution dedicated to the prevention and cure of cancer and other life-threatening illness.
Best Of logoCity of Hope has been named one of "America's Best Hospitals" in cancer and gynecology by U.S. News & World Report. Read more here...
NCI CCC LogoThe National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer.
Best Of logoWe subscribe to the HONcode of the Healthcare on the Net Foundation.